JP2013006854A5 - - Google Patents

Download PDF

Info

Publication number
JP2013006854A5
JP2013006854A5 JP2012191753A JP2012191753A JP2013006854A5 JP 2013006854 A5 JP2013006854 A5 JP 2013006854A5 JP 2012191753 A JP2012191753 A JP 2012191753A JP 2012191753 A JP2012191753 A JP 2012191753A JP 2013006854 A5 JP2013006854 A5 JP 2013006854A5
Authority
JP
Japan
Prior art keywords
halogen atom
alkyl group
thio
hydrogen atom
glucitol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012191753A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013006854A (ja
JP5660094B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2012191753A priority Critical patent/JP5660094B2/ja
Priority claimed from JP2012191753A external-priority patent/JP5660094B2/ja
Publication of JP2013006854A publication Critical patent/JP2013006854A/ja
Publication of JP2013006854A5 publication Critical patent/JP2013006854A5/ja
Application granted granted Critical
Publication of JP5660094B2 publication Critical patent/JP5660094B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012191753A 2009-04-16 2012-08-31 併用医薬 Expired - Fee Related JP5660094B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2012191753A JP5660094B2 (ja) 2009-04-16 2012-08-31 併用医薬

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009100210 2009-04-16
JP2009100210 2009-04-16
JP2012191753A JP5660094B2 (ja) 2009-04-16 2012-08-31 併用医薬

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2011540651A Division JP5077786B2 (ja) 2009-04-16 2010-04-16 併用医薬

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014245257A Division JP5910711B2 (ja) 2009-04-16 2014-12-03 併用医薬

Publications (3)

Publication Number Publication Date
JP2013006854A JP2013006854A (ja) 2013-01-10
JP2013006854A5 true JP2013006854A5 (enExample) 2013-05-30
JP5660094B2 JP5660094B2 (ja) 2015-01-28

Family

ID=42982643

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2011540651A Active JP5077786B2 (ja) 2009-04-16 2010-04-16 併用医薬
JP2012191753A Expired - Fee Related JP5660094B2 (ja) 2009-04-16 2012-08-31 併用医薬
JP2014245257A Active JP5910711B2 (ja) 2009-04-16 2014-12-03 併用医薬
JP2015253932A Active JP6066144B2 (ja) 2009-04-16 2015-12-25 併用医薬

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2011540651A Active JP5077786B2 (ja) 2009-04-16 2010-04-16 併用医薬

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014245257A Active JP5910711B2 (ja) 2009-04-16 2014-12-03 併用医薬
JP2015253932A Active JP6066144B2 (ja) 2009-04-16 2015-12-25 併用医薬

Country Status (30)

Country Link
US (1) US20120040898A1 (enExample)
EP (3) EP2601949B1 (enExample)
JP (4) JP5077786B2 (enExample)
KR (2) KR20120016051A (enExample)
CN (7) CN105434430A (enExample)
AR (1) AR076317A1 (enExample)
AU (1) AU2010237748B2 (enExample)
BR (1) BRPI1012539A2 (enExample)
CA (1) CA2755392A1 (enExample)
CY (2) CY1114703T1 (enExample)
DK (2) DK2419097T3 (enExample)
ES (2) ES2431300T3 (enExample)
HK (6) HK1217302A1 (enExample)
HR (2) HRP20131120T1 (enExample)
ME (2) ME02015B (enExample)
MX (1) MX2011010901A (enExample)
MY (3) MY182720A (enExample)
NZ (4) NZ595314A (enExample)
PH (3) PH12015500235A1 (enExample)
PL (2) PL2601949T3 (enExample)
PT (2) PT2419097E (enExample)
RS (2) RS53761B1 (enExample)
RU (2) RU2532330C2 (enExample)
SG (6) SG175154A1 (enExample)
SI (2) SI2601949T1 (enExample)
SM (1) SMT201500015B (enExample)
TW (3) TW201500043A (enExample)
UA (2) UA105216C2 (enExample)
WO (1) WO2010119990A1 (enExample)
ZA (1) ZA201106727B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
EP4684831A3 (en) 2009-02-13 2026-03-11 Boehringer Ingelheim International GmbH Sglt2 inhibitor for improving glycemic control
BR112012007085B8 (pt) 2009-09-30 2021-05-25 Boehringer Ingelheim Int processos para a preparação de derivados de benzil-benzeno substituídos com glicopiranosila
UY32919A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
US20120283169A1 (en) * 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TR201101809A1 (tr) * 2010-12-21 2012-07-23 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Vildagliptin ve glimepirid kombinasyonları.
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
SG11201406987UA (en) 2012-05-17 2014-12-30 Transtech Pharma Llc Glucokinase activator compositions for the treatment of diabetes
HK1208621A1 (en) * 2012-08-30 2016-03-11 大正制药株式会社 Combination of sglt2 inhibitor and anti-hypertension drug
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TR201901110T4 (tr) 2013-04-05 2019-02-21 Boehringer Ingelheim Int Empagliflozinin terapötik kullanımları.
HK1215378A1 (zh) 2013-04-18 2016-08-26 勃林格殷格翰国际有限公司 药物组合物、治疗方法及其用途
TW201636015A (zh) * 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
KR102060728B1 (ko) * 2015-02-27 2019-12-30 재단법인 아산사회복지재단 Dpp-4 억제제를 포함하는 판막 석회화의 예방 또는 치료용 조성물
CN105963280B (zh) * 2016-06-30 2018-11-06 合肥华方医药科技有限公司 一种伏格列波糖口腔速溶膜及其制备方法
EP3528800A1 (en) 2016-10-19 2019-08-28 Boehringer Ingelheim International GmbH Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
AU2017357589B2 (en) 2016-11-10 2023-05-11 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11439689B2 (en) * 2016-11-14 2022-09-13 Kaohsiung Medical University Method for detecting whether glucose metabolism is abnormal, and prevention and treatment therefor
AU2019254371A1 (en) 2018-04-17 2020-10-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
KR20190137343A (ko) 2018-06-01 2019-12-11 김유찬 계량 인덕션
KR20210020866A (ko) 2018-06-12 2021-02-24 브이티브이 테라퓨틱스 엘엘씨 인슐린 또는 인슐린 유사체와 조합된 글루코키나제 활성제의 치료적 용도
CN112955215B (zh) 2018-10-29 2024-05-17 勃林格殷格翰国际有限公司 吡啶基磺酰胺衍生物、药物组合物及其用途
CN112955214B (zh) 2018-10-29 2024-05-07 勃林格殷格翰国际有限公司 吡啶基磺酰胺衍生物、药物组合物及其用途
WO2021167840A1 (en) 2020-02-18 2021-08-26 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4432757A1 (de) 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
JP2003520759A (ja) 1999-08-31 2003-07-08 アンドルックス ファーマスーティカルズ インコーポレーテッド 単位核を有する徐放性錠剤
US20030045553A1 (en) 2001-04-04 2003-03-06 Bussolari Jacqueline C. Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators
ATE318272T1 (de) * 2001-04-11 2006-03-15 Bristol Myers Squibb Co Aminosäurekomplexe von c-arylglycosiden zur behandlung von diabetes und verfahren
TW200637839A (en) * 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
CA2655937A1 (en) * 2006-06-29 2008-01-03 Taisho Pharmaceutical Co., Ltd. C-phenyl 1-thioglucitol compound
JP5194588B2 (ja) * 2006-07-06 2013-05-08 大正製薬株式会社 1−チオ−d−グルシトール誘導体を有効成分として含有する糖尿病の予防又は治療剤
EP2054426A1 (en) * 2006-08-15 2009-05-06 Boehringer Ingelheim International GmbH Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
EA018495B1 (ru) * 2006-11-09 2013-08-30 Бёрингер Ингельхайм Интернациональ Гмбх Комбинированное лечение ингибиторами sglt-2 (натрийзависимый сопереносчик глюкозы 2) и содержащими их фармацевтическими композициями
AU2007332476A1 (en) * 2006-12-14 2008-06-19 Taisho Pharmaceutical Co., Ltd. 1-phenyl 1-thio-D-glucitol derivative
CL2008002425A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composición farmacéutica que comprende un inhibidor de sglt2 y 1-(4-metil-quinazolin-2-il)metil-3metil-7-(-2-butin-1-il)-8-(3-(r)-amino-piperidin-1il)-xantina, un inhibidor de dpp iv y su uso para el tratamiento de la obesidad y de la diabetes tipo 1 y 2 y complicaciones de esta.
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.

Similar Documents

Publication Publication Date Title
JP2013006854A5 (enExample)
RU2011146335A (ru) Фармацевтические композиции
EP2275108B1 (en) Pharmaceutical preparation comprising dpp-iv inhibitor and other diabetes therapeutic agent in concomitant or combined form
JP2011504903A5 (enExample)
JP2008007519A5 (enExample)
CY1116799T1 (el) Προληψη της υπογλυκαιμιας σε ασθενεις με σακχαρωδη διαβητη τυπου 2
CA2789665A1 (en) Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases
JP2018502101A5 (enExample)
JP2011509922A5 (enExample)
JP2012533546A5 (enExample)
JP2014500295A5 (enExample)
CY1113755T1 (el) Η λιξισενατιδη ως επιπροσθετη αγωγη στην ινσουλινη γλαργινη και στη μετφορμινη για τη θεραπευτικη αντιμετωπιση του διαβητη τυπου 2
JP2009542702A5 (enExample)
JP2018504393A5 (enExample)
JP2013508279A5 (enExample)
JP2017505293A5 (enExample)
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
RU2013155586A (ru) [1,3]оксазины
JP2012530779A5 (enExample)
JP2016534124A5 (enExample)
JP2016505637A5 (enExample)
JP2015524472A5 (enExample)
JP2008519840A5 (enExample)
JP2014528464A5 (enExample)
JP2015172098A5 (enExample)